AUA 2015 Research Highlights For IC and Pelvic Pain - BotoxA, Microbiome, Pudendal Stimulation, Hunner's Lesion Treatment, Triamcinolone

AUA 2015 Research Highlights For IC and Pelvic Pain – BotoxA, Microbiome, Pudendal Stimulation, Hunner’s Lesion Treatment, Triamcinolone

Each year, promising new studies on interstitial cystitis, bladder pain syndrome and chronic pelvic pain syndrome are presented at the annual meeting of the American Urology Association. Here are the IC/BPS research highlights for AUA 2015. The full abstracts can be viewed at: http://www.aua2015.org/

Quitting Smoking Improves Outcome in Urologic Disease

Researchers at the Henry Ford Health System studied the records of 9,014 patients who underwent one of three urologic surgeries. Their results found that current smokers had significantly higher odds for respiratory and kidney complications and increased odds for longer hospital stay and for needing additional procedures. Former smokers, who had quit for atleast a year, faired far better. “This research serves as a wakeup call to many smokers and demonstrates that the sooner you quite, the sooner your risk factors for surgical complications.. decrease” according to Dr. Benjamin Davies (UPITT). Read more!

In a second study, they found that bladder cancer patients greatly reduced their risk of recurring cancer if they refrained from smoking 15 years or more! Read more!

Tanezumab Reduces Pain in Women With IC

Researchers led by J. Curtis Nickel MD in Canada found that Tanezumab, a nerve growth factor inhibitor, reduce the pain of IC in three clinical trials. The found that women with IC were significantly more responsive than men with chronic prostatitis to TMZ! Source: PD20-03

BotoxA in a Hydrogel Slow Release Delivery System

Researchers in Israel used a new method to deliver BotoxA to the bladder, a hydrogel that is placed into the bladder, solidifies and then, over 6 to 8 hours, released BotoxA. A single instillation was performed on 15 severe IC patients. Some side effects were reported including one severe episodeof lympthadenopathy, 3 cases of mild constipation, UTI, flu and one patient who developed depression. Bladder symptoms of frequency, nocturia and urgency decreased up to week six but returned to baseline by week 12. Further research is needed, including a randomized controlled trial. Source: PD20-03

Single Injection Botulinum Toxin A

Researchers in Taiwan onducted the first randomized, double blind placebo controlled study comparing a single Botox A injection to a control of normal saline. Sixty patients participated. The overall success rates were 63% for the Botox Group and just 15% for the saline group. Source: PD20-02

Altered Microbiome in Chronic Pelvic Pain Patients

The NIDDK funded MAPP study conducted both fecal and vaginal flora studies and found that there were consistent differences between IC patients and controls and that when given to mice, they differentially modulated pelvic pain. These may be new biomarkers that could be used for the diagnosis of IC. Source: PD20-09

Pudendal Nerve Stimulation

Researchers compared, contrasted and compared methods for performing pudendal nerve stimulation, concluding that the STAR-approach was standardized and optimal for the placement of leads. Source: PD20-06

Hydrodistention or Fulguration For Hunner’s Lesions

Researchers in Korea compared the fulguration of lesion with a simple hydrodistention for the treatmet of IC/BPS. The results were not suprising with fulguration patients experiencing more pain reduction and lower symptoms. They say that fulguration should remain the choice treatment for Hunner’s lesions. Source: PD20-10

Triamincinolone Therapy Found Effective for Hunner’s lesions

Because fulguration of lesions can cause bladder wall scarring and limit bladder capacity over the long term, finding a less traumatic therapy is important. This study evaluated the effect of triamcinolone injections into ulcers in 29 patients. The results were effective and durable. Source: PD20-11

By Jill Osborne|2017-01-18T12:03:15-08:00May 28th, 2015|Conference Reports, Interstitial Cystitis IC/BPS, Our Blog, Research|Comments Off

About the Author: Jill Osborne

My Google Profile+ Jill Heidi Osborne is the president and founder of the Interstitial Cystitis Network, a health education company dedicated to interstitial cystitis, bladder pain syndrome and other pelvic pain disorders. As the editor and lead author of the ICN and the IC Optimist magazine, Jill is proud of the academic recognition that her website has achieved. The University of London rated the ICN as the top IC website for accuracy, credibility, readability and quality. (Int Urogynecol J - April 2013). Harvard Medical School rated both Medscape and the ICN as the top two websites dedicated to IC. (Urology - Sept 11). For many years, Jill served on the Congressionally Directed Medical Research Panel (US Army) where she collaborated with researchers to evaluate new IC research studies for possible funding. Jill has conducted and/or collaborates on a variety of IC research studies on new therapeutics, pain care, sexuality, the use of medical marijuana, menopause and the cost of treatments, shining a light on issues that influence patient quality of life. An IC support group leader and national spokesperson for the past 20 years, she has represented the IC community on radio, TV shows, at medical conferences. She has written hundreds of articles on IC and its related conditions. Jill has a Bachelors Degree in Pharmacology and a Masters in Psychology, Jill was named Presidential Management Intern (aka Fellowship) while in graduate school. (She was unable to earn her PhD due to the onset of her IC.) She spends the majority of her time providing WELLNESS COACHING for patients in need and developing new, internet based educational and support tools for IC patients, including new live IC Support Group Meetings via Youtube and the “Living with IC” video series. Jill was diagnosed with IC at the age of 32 but first showed symptoms at the age of 12.